Anti-inflammatory and antioxidant effects of ranolazine on primary cultured astrocytes
Critical Care volume 18, Article number: P447 (2014)
Because of its ability to block late INa , ranolazine is used as an antianginal agent for the treatment of chronic angina pectoris when angina is not adequately controlled by other agents . Besides its cardiovascular effects, ranolazine improves different neuronal functions, and thus its use has been proposed for the treatment of pain and epileptic disorders [3, 4]. Since astrocytes are involved in neuronal inflammatory processes, and autoimmune and neurodegenerative diseases , we have investigated the antiinflammatory and antioxidant effects of ranolazine in primary cultured astrocytes.
We incubated differentiated rat astrocytes in primary culture (10 days of culture)  for 24 hours with ranolazine (10-5, 10-6, 10-7 M). We measured the protein expression levels of PPARy and Cu/Zn-SOD by western blot technique. Protective effect of ranolazine on cell viability was assayed using MTT conversion assay. Finally, to evaluate the effect of ranolazine on the IL-1β cytokine and TNFα mediators, we used the enzyme-linked immunosorbent assay technique.
Compared with control cells, treatment with ranolazine induced an increment of anti-inflammatory PPARy and reduced the proinflammatory mediators IL-1 β and TNFα in primary cultured astrocytes. Ranolazine (10-6 M) also increased the expression of antioxidant protein Cu/Zn-SOD and caused a significant increase in cell viability.
Ranolazine decreases inflammatory mediators IL-1 β and TNFα, and increases anti-inflammatory PPARy as well as the antioxidant Cu/Zn-SOD in astrocytes in culture. These results suggest that ranolazine could be useful as a neuroprotective drug in pathologies inducing inflammatory damage and oxidant processes.
Belardinelli L, et al.: J Pharmacol Exp Ther. 2013, 344: 23-32. 10.1124/jpet.112.198887
Siddiqui MA, et al.: Drugs. 2006, 66: 693-710. 10.2165/00003495-200666050-00010
Park YY, et al.: J Neurophysiol. 2013, 109: 1378-1390. 10.1152/jn.00435.2012
Ka h, lig KM, et al.: Br J Pharmacol. 2010, 161: 1414-1426. 10.1111/j.1476-5381.2010.00976.x
Vallés SL, et al.: Brain Pathol. 2004, 14: 365-371.
About this article
Cite this article
El Amrani, F., Guerra, S., Aguirre-Rueda, D. et al. Anti-inflammatory and antioxidant effects of ranolazine on primary cultured astrocytes. Crit Care 18 (Suppl 1), P447 (2014). https://doi.org/10.1186/cc13637